Journal of Biosciences

, Volume 41, Issue 3, pp 407–417 | Cite as

Sirtuin 1 and 7 mediate resveratrol-induced recovery from hyper-anxiety in high-fructose-fed prediabetic rats

  • B Raghunath Reddy
  • Swati Maitra
  • Priya Jhelum
  • K Praveen Kumar
  • Pankaj K Bagul
  • Gagandeep Kaur
  • Sanjay K Banerjee
  • Arvind Kumar
  • Sumana ChakravartyEmail author


Hyperglycaemia in diabetes is either caused by reduced availability of insulin (type 1 diabetes, T1D) or insulin resistance to the cells (type 2 diabetes, T2D). In recent years, the prevalence of T2D has increased to an alarming proportion, encompassing 95% of the total diabetic burden, probably due to economy-driven changes in lifestyle. Recent epidemiological studies show comorbid depression, anxiety and related mental illness. To explore the molecular mechanisms underlying this comorbid conditions, we used Sprague–Dawley rats on high-fructose diet for 8 weeks to induce prediabetic condition. Rats with this metabolic syndrome also showed hyper-anxiety when they were subjected to anxiety-related behavioural assays. Rats were administered with resveratrol, an activator of sirtuins, and metformin, a standard antidiabetic drug, simultaneously with fructose. We observed that resveratrol was more effective in protecting from both the metabolic (prediabetic) and affective (anxiety) disorders than metformin. Molecular studies showed that recovery was associated with the upregulation of few nuclear sirtuins that act epigenetically – Sirt 1 and 7, which were significantly attenuated in the striatum of prediabetic rats. In conclusion, our study showed that hyper-anxiety associated with prediabetic condition is ameliorated by resveratrol through modulation of sirtuins, which is more or less similar to metformin.


Epigenetic fructose metformin mood disorders sirtuins type 2 diabetes 



The project was initiated under the Ramalingaswami Re-entry Individual Fellowships to SC and SKB by the Department of Biotechnology, India, and supported by the Council of Scientific and Industrial Research (CSIR) network projects [BSC0103-UNDO to SC, SKB and AK]. SM, PKB and BRR wish to thank CSIR for their SRFs. The authors would like to thank Pranav C Joshi for the help in preparing the manuscript.

Supplementary material

12038_2016_9627_MOESM1_ESM.pdf (321 kb)
ESM 1 (PDF 320 kb)


  1. Albani D, Polito L, Signorini A and Forloni G 2010 Neuroprotective properties of resveratrol in different neurodegenerative disorders. BioFactors 36 370–376CrossRefPubMedGoogle Scholar
  2. Alwan A 2011 Global status report on noncommunicable diseases 2010: World Health OrganizationGoogle Scholar
  3. American Diabetes Association 2014 Diagnosis and classification of diabetes mellitus. Diabetes Care 37 S81–S90Google Scholar
  4. Ates O, Cayli SR, Yucel N, Altinoz E, Kocak A, Durak MA, et al. 2007 Central nervous system protection by resveratrol in streptozotocin-induced diabetic rats. J Clin Neurosci. 14 256–260CrossRefPubMedGoogle Scholar
  5. Bagul PK and Banerjee SK 2013 Insulin resistance, oxidative stress and cardiovascular complications: role of sirtuins. Curr. Pharm. Des. 19 5663–5677CrossRefPubMedGoogle Scholar
  6. Bagul P and Banerjee S 2015 Application of resveratrol in diabetes: rationale, strategies and challenges. Curr Mol Med. 15 312–330CrossRefPubMedGoogle Scholar
  7. Bagul PK, Middela H, Matapally S, Padiya R, Bastia T, Madhusudana K, et al. 2012 Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats. Pharmacol. Res. 66 260–268CrossRefPubMedGoogle Scholar
  8. Bagul PK, Deepthi N, Sultana R and Banerjee SK 2015 Resveratrol ameliorates cardiac oxidative stress in diabetes through deacetylation of NFkB-p65 and histone 3. J. Nutr. Biochem. 26 1298–1307CrossRefPubMedGoogle Scholar
  9. Bernstein CM, Stockwell MS, Gallagher MP, Rosenthal SL and Soren K 2013 Mental health issues in adolescents and young adults with type 1 diabetes: prevalence and impact on glycemic control. Clin. Pediatr. 52 10–15CrossRefGoogle Scholar
  10. Cade WT 2008 Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys. Ther. 88 1322–1335CrossRefPubMedPubMedCentralGoogle Scholar
  11. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, et al. 2009 AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458 1056–1060CrossRefPubMedPubMedCentralGoogle Scholar
  12. Chakraborty A, Chowdhury S and Bhattacharyya M 2011 Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res. Clin. Pract. 93 56–62CrossRefPubMedGoogle Scholar
  13. Chakravarty S, Pathak SS, Maitra S, Khandelwal N, Chandra KB and Kumar A 2014 Epigenetic regulatory mechanisms in stress-induced behavior. Int. Rev. Neurobiol. 115 117–154CrossRefPubMedGoogle Scholar
  14. Collins MM, Corcoran P and Perry IJ 2009 Anxiety and depression symptoms in patients with diabetes. Diabet Med. 26 153–161CrossRefPubMedGoogle Scholar
  15. Correia S, Carvalho C, Santos MS, Proenca T, Nunes E, Duarte AI, et al. 2008 Metformin protects the brain against the oxidative imbalance promoted by type 2 diabetes. Med. Chem. 4 358–364CrossRefPubMedGoogle Scholar
  16. Diamond J 2011 Medicine: Diabetes in India. Nature 469 478–479CrossRefPubMedGoogle Scholar
  17. Ducat LJ, Philipson LH and Anderson BJ 2014 Routine depression screening for patients with diabetes--reply. JAMA. 312 2413CrossRefPubMedGoogle Scholar
  18. Ducat L, Rubenstein A, Philipson LH and Anderson BJ 2015 A review of the mental health issues of diabetes conference. Diabetes Care 38 333–338CrossRefPubMedPubMedCentralGoogle Scholar
  19. Dudley KJ, Li X, Kobor MS, Kippin TE and Bredy TW 2011 Epigenetic mechanisms mediating vulnerability and resilience to psychiatric disorders. Neurosci. Biobehav. Rev. 35 1544–1551CrossRefPubMedGoogle Scholar
  20. Esteghamati A, Eskandari D, Mirmiranpour H, Noshad S, Mousavizadeh M, Hedayati M, et al. 2013 Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: a randomized clinical trial. Clin. Nutr. 32 179–185CrossRefPubMedGoogle Scholar
  21. Farvid MS, Qi L, Hu FB, Kawachi I, Okereke OI, Kubzansky LD, et al. 2014 Phobic anxiety symptom scores and incidence of type 2 diabetes in US men and women. Brain Behav. Immun. 36 176–182CrossRefPubMedGoogle Scholar
  22. Gale EA and Gillespie KM 2001 Diabetes and gender. Diabetologia 44 3–15CrossRefPubMedGoogle Scholar
  23. Giacco F and Brownlee M 2010 Oxidative stress and diabetic complications. Circ. Res. 107 1058–1070CrossRefPubMedPubMedCentralGoogle Scholar
  24. Griebel G, Perrault G and Sanger DJ 1997 Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs. Psychopharmacology. 131 180–186CrossRefPubMedGoogle Scholar
  25. Haigis MC and Guarente LP 2006 Mammalian sirtuins--emerging roles in physiology, aging, and calorie restriction. Genes Dev. 20 2913–2921CrossRefPubMedGoogle Scholar
  26. Jiang Y, Langley B, Lubin FD, Renthal W, Wood MA, Yasui DH, et al. 2008 Epigenetics in the nervous system. J Neurosci. 28 11753–11759CrossRefPubMedPubMedCentralGoogle Scholar
  27. Jiang T, Yu JT, Zhu XC, Wang HF, Tan MS, Cao L, et al. 2014 Acute metformin preconditioning confers neuroprotection against focal cerebral ischaemia by pre‐activation of AMPK‐dependent autophagy. Br. J. Pharmacol. 171 3146–3157CrossRefPubMedPubMedCentralGoogle Scholar
  28. Kesebir S 2014 Metabolic syndrome and childhood trauma: Also comorbidity and complication in mood disorder. World J Clin Cases 2 332–337CrossRefPubMedPubMedCentralGoogle Scholar
  29. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. 2006 Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127 1109–1122CrossRefPubMedGoogle Scholar
  30. Li J, Benashski SE, Venna VR and McCullough LD 2010 Effects of metformin in experimental stroke. Stroke 41 2645–2652CrossRefPubMedPubMedCentralGoogle Scholar
  31. Liu Y, Gerber R, Wu J, Tsuruda T and McCarter JD 2008 High-throughput assays for sirtuin enzymes: a microfluidic mobility shift assay and a bioluminescence assay. Anal. Biochem. 378 53–59CrossRefPubMedGoogle Scholar
  32. Liu Z, Cao J, Gao X, Zhou Y, Wen L, Yang X, et al. 2011 CPLA 1.0: an integrated database of protein lysine acetylation. Nucleic Acids Res. 39 D1029–D1034CrossRefPubMedGoogle Scholar
  33. Luchsinger JA 2010 Diabetes, related conditions, and dementia. J. Neurol. Sci. 299 35–38CrossRefPubMedPubMedCentralGoogle Scholar
  34. Mao Z, Hine C, Tian X, Van Meter M, Au M, Vaidya A, et al. 2011 SIRT6 promotes DNA repair under stress by activating PARP1. Science 332 1443–1446CrossRefPubMedGoogle Scholar
  35. Maritim AC, Sanders RA and Watkins JB 3rd 2003 Diabetes, oxidative stress, and antioxidants: a review. J. Biochem. Mol. Toxicol. 17 24–38CrossRefPubMedGoogle Scholar
  36. Mathers CD and Loncar D 2006 Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3 e442CrossRefPubMedPubMedCentralGoogle Scholar
  37. McNay EC and Recknagel AK 2011 Brain insulin signaling: a key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. Neurobiol. Learn. Mem. 96 432–442CrossRefPubMedPubMedCentralGoogle Scholar
  38. Miatello R, Vazquez M, Renna N, Cruzado M, Zumino AP and Risler N 2005 Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am. J. Hypertens 18 864–870Google Scholar
  39. Nemoto S, Fergusson MM and Finkel T 2005 SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J. Biol. Chem. 280 16456–16460CrossRefPubMedGoogle Scholar
  40. Ohkawa H, Ohishi N and Yagi K 1979 Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95 351–358CrossRefPubMedGoogle Scholar
  41. Padiya R, Khatua TN, Bagul PK, Kuncha M and Banerjee SK 2011 Garlic improves insulin sensitivity and associated metabolic syndromes in fructose fed rats. Nutr Metab. 8 53CrossRefGoogle Scholar
  42. Pintana H, Apaijai N, Pratchayasakul W, Chattipakorn N and Chattipakorn SC 2012 Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats. Life Sci. 91 409–414CrossRefPubMedGoogle Scholar
  43. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM and Puigserver P 2005 Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434 113–118CrossRefPubMedGoogle Scholar
  44. Sacharczuk M, Juszczak G, Swiergiel AH, Jaszczak K, Lipkowski AW and Sadowski B 2009 Alcohol reverses depressive and pronociceptive effects of chronic stress in mice with enhanced activity of the opioid system. Acta Neurobiol. Exp. 69 459–468Google Scholar
  45. Schmatz R, Mazzanti CM, Spanevello R, Stefanello N, Gutierres J, Correa M, et al. 2009 Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 610 42–48CrossRefPubMedGoogle Scholar
  46. Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C and White RD 2006 Physical activity/exercise and type 2 diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 29 1433–1438CrossRefPubMedGoogle Scholar
  47. Sojitra B, Bulani Y, Putcha UK, Kanwal A, Gupta P, Kuncha M, et al. 2012 Nitric oxide synthase inhibition abrogates hydrogen sulfide-induced cardioprotection in mice. Mol. Cell. Biochem. 360 61–69CrossRefPubMedGoogle Scholar
  48. Sun C, Zhang F, Ge X, Yan T, Chen X, Shi X, et al. 2007 SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab. 6 307–319CrossRefPubMedGoogle Scholar
  49. Tsankova N, Renthal W, Kumar A and Nestler EJ 2007 Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci. 8 355–367CrossRefPubMedGoogle Scholar
  50. Urdinguio RG, Sanchez-Mut JV and Esteller M 2009 Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol. 8 1056–1072CrossRefPubMedGoogle Scholar
  51. Vakhrusheva O, Smolka C, Gajawada P, Kostin S, Boettger T, Kubin T, et al. 2008 Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ. Res. 102 703–710CrossRefPubMedGoogle Scholar
  52. Volmar C-H and Wahlestedt C 2015 Histone deacetylases (HDACs) and brain function. Neuroepigenetics 1 20–27CrossRefGoogle Scholar

Copyright information

© Indian Academy of Sciences 2016

Authors and Affiliations

  • B Raghunath Reddy
    • 1
  • Swati Maitra
    • 1
  • Priya Jhelum
    • 1
  • K Praveen Kumar
    • 1
  • Pankaj K Bagul
    • 2
  • Gagandeep Kaur
    • 2
  • Sanjay K Banerjee
    • 2
    • 3
  • Arvind Kumar
    • 4
  • Sumana Chakravarty
    • 1
    Email author
  1. 1.Chemical BiologyIndian Institute of Chemical Technology (IICT)HyderabadIndia
  2. 2.Medicinal Chemistry and PharmacologyIndian Institute of Chemical Technology (IICT)HyderabadIndia
  3. 3.Drug Discovery Research Center (DDRC)Translational Health Science and Technology Institute (THSTI)FaridabadIndia
  4. 4.Centre for Cellular and Molecular Biology (CCMB)HyderabadIndia

Personalised recommendations